1-甲基苯并-2-磺酸 | 5533-38-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: 1-甲基苯并-2-磺酸
• 中文别名: 1-甲基苯并-2-磺酸,99；1-甲基苯并咪唑-2-磺酸
• 英文名称: 1-methyl-1H-benzo[d]imidazole-2-sulfonic acid
• 英文别名: 1-methyl-1H-benzimidazole-2-sulfonic acid；1-Methylbenzimidazole-2-sulfonic Acid；1-metylbenzimidazole-2-sulfonic acid；1-methyl-1H-benzoimidazole-2-sulfonic acid；1-methyl-1H-benzoimidazole-2-sulfonic acid；1-Methyl-benzimidazol-2-sulfonsaeure
• CAS: 5533-38-0
• 化学式: C₈H₈N₂O₃S
• mdl: MFCD00142670
• 分子量: 212.229
• InChiKey: IPGCDDVLUYNFOU-UHFFFAOYSA-N

物化性质

• 熔点：
  341 °C
• 密度：
  1.4306 (rough estimate)
• 溶解度：
  31.5 [ug/mL]
• 稳定性/保质期：
  避免与不相容的材料接触。与强氧化剂反应。

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  85.2
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 安全说明：
  S24/25
• 海关编码：
  2933990090

SDS

Name:	1-Methylbenzimidazole-2-sulfonic acid 99% Material Safety Data Sheet
Synonym:	None listed
CAS:	5533-38-0

Section 1 - Chemical Product MSDS Name:1-Methylbenzimidazole-2-sulfonic acid 99% Material Safety Data Sheet
Synonym:None listed

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
5533-38-0	1-Methylbenzimidazole-2-sulfonic acid	99	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Sweep up or absorb material, then place into a suitable clean, dry, closed container for disposal. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 5533-38-0: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder
Color: off-white
Odor: none reported
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 329 - 331 deg C
Autoignition Temperature: Not applicable.
Flash Point: Not applicable.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature: Not available.
Solubility in water: Not available.
Specific Gravity/Density: Not available.
Molecular Formula: C8H8N2O3S
Molecular Weight: 212.23

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, dust generation.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, oxides of nitrogen, oxides of sulfur, irritating and toxic fumes and gases, carbon dioxide.
Hazardous Polymerization: Has not been reported.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 5533-38-0 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
1-Methylbenzimidazole-2-sulfonic acid - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 5533-38-0: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 5533-38-0 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 5533-38-0 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-甲基苯并-2-磺酸 在 乙酸铵 作用下， 反应 3.0h， 以64%的产率得到2-氨-1-甲基苯咪唑
  参考文献：
  名称：

  N-取代苯并咪唑-2-磺酸的合成及部分转化

  摘要：

  DOI：

  10.1007/s10593-006-0112-4
• 作为产物：
  描述：

  1-甲基-1H-苯并咪唑-2-硫醇 在 sodium hydroxide 、 双氧水 作用下， 以 水 为溶剂， 生成 1-甲基苯并-2-磺酸
  参考文献：
  名称：

  苯并恶唑的缩合衍生物。1. 6和5取代的苯并咪唑并[2,1-b]喹唑啉-12-ones的合成

  摘要：

  DOI：

  10.1007/bf00472263

文献信息

• Reductive dehalogenation and dehalogenative sulfonation of phenols and heteroaromatics with sodium sulfite in an aqueous medium
  作者：Monika Tomanová、Lukáš Jedinák、Petr Cankař

  DOI：10.1039/c9gc00467j

  日期：——

  Prototropic tautomerism was used as a tool for the reductive dehalogenation of (hetero)aryl bromides and iodides, or dehalogenative sulfonation of (hetero)aryl chlorides and fluorides, using sodium sulfite as the sole reagent in an aqueous medium. This protocol does not require a metal or phase transfer catalyst and avoids using organic solvent as the reaction medium. This method is especially suitable

  质子互变异构被用作在水介质中使用亚硫酸钠作为唯一试剂的（杂）芳基溴化物和碘化物的还原性脱卤化或（杂）芳基氯和氟化物的脱卤化磺化的工具。该方案不需要金属或相转移催化剂，避免使用有机溶剂作为反应介质。此方法特别适用于容易互变异构的底物（例如2-或4-卤代氨基酚和4-卤代间苯二酚），在温和的反应条件下（≤60°C）会进行脱卤或磺化。由于亚硫酸钠是一种廉价，安全且对环境无害的试剂，因此该方法至少具有三个潜在应用：（i）使用亚硫酸钠作为还原剂对卤素作为保护基进行脱保护；（ii）在温和的反应条件下磺化芳族卤化物，避免使用危险和腐蚀性的试剂/溶剂；（iii）将有毒的卤代芳族化合物转化为危害较小的化合物。
• Prototropic equilibrium in 1(11)H-2, 3, 4, 5-tetrahydro[1, 3]diazepino[1, 2-a]benzimidazole, synthesis and pharmacological properties of its N-substituted derivatives
  作者：A. S. Morkovnik、A. A. Spasov、T. A. Kuz’menko、A. F. Kucheryavenko、L. N. Divaeva、Yu. V. Koshchienko、V. A. Anisimova、L. G. Kuzmina、N. V. Rogova、V. A. Kuznetsova、N. I. Chepljaeva、O. A. Solovyova、A. S. Taran、E. S. Vorobiev、D. A. Aleshin、V. S. Sirotenko、K. A. Gajdukova、M. V. Bogoslavtseva

  DOI：10.1007/s11172-015-1200-3

  日期：2015.11

  Based on the X-ray crystallography and 1H NMR spectroscopy data and quantum chemical studies, it was found that 1(11)H-2, 3, 4, 5-tetrahydro[1, 3]diazepino[1, 2-a]benzimidazole (1) exists almost exclusively in the 1H-prototropic form. To prepare the fixed 11H-diazepinobenzimidazole forms of 1, 1-R-2-(4-chlorobutylamino)benzimidazoles (R = Me, N=CHAr) were synthesized, which underwent thermal cyclization with the formation of a mixture of 11-Rsubstituted diazepine 1 and 1-R-2-(pyrrolidin-1-yl)benzimidazole. Alkylation of diazepine 1 in a neutral medium regioselectively gave 11-R-diazepinobenzimidazoles in high yield. Their 1-substituted isomers were obtained by carrying out this reaction in the system NaH—THF. The N(11)-derivatives of diazepinobenzimidazole 1 were found to inhibit dipeptidyl peptidase 4 (DPP-4), but less actively than a comparator drug sitagliptin. The compounds under study did not exhibit antiglycation action in vitro and virtually did not affect activity of α-glucosidase and glycogen phosphorylase. However, they are characterized by a strong antiaggregant effect, making these derivatives promising for further studies.

  基于X射线晶体学、1H NMR光谱数据和量子化学研究，发现1(11)H-2,3,4,5-四氢[1,3]二氮杂环[1,2-a]苯并咪唑（1）几乎完全以1H-质子化形式存在。为了制备固定化的11H-二氮杂环苯并咪唑形式1，合成了1-R-2-(4-氯丁胺)苯并咪唑（R=Me，N=CHAr），它们经过热环化反应，形成11-R取代的二氮杂环1和1-R-2-（吡咯烷-1-基）苯并咪唑的混合物。二氮杂环1在中性介质中的烷基化反应选择性地得到高产率的11-R-二氮杂环苯并咪唑。它们的1-取代异构体是通过在NaH-THF体系中进行此反应得到的。发现二氮杂环苯并咪唑1的N(11)衍生物抑制二肽基肽酶4（DPP-4），但活性低于对照药物西他列汀。所研究的化合物在体外未表现出抗糖基化作用，并且几乎不影响α-葡萄糖苷酶和糖原磷酸化酶的活性。然而，它们的特点是具有强大的抗聚集作用，使这些衍生物有望进一步研究。
• Quaternary ammonium salts of substituted pyrazoline compounds, their preparation and use as medicaments
  申请人：LABORATORIOS DEL DR. ESTEVE, S.A.

  公开号：EP1749821A1

  公开（公告）日：2007-02-07

  The present invention relates to quaternary ammonium salts of substituted pyrazoline compounds of formula I, methods for their preparation, medicaments comprising theses compounds as well as their use for the preparation of a medicament for the treatment of humans and animals.

  本发明涉及公式I的取代吡唑烯化合物的季铵盐，其制备方法，包含这些化合物的药物以及它们用于制备用于治疗人类和动物的药物的用途。
• 3- or 4-monosubstituted phenol and thiophenol derivatives useful as H3 ligands
  申请人：Bernardelli Patrick

  公开号：US20050267095A1

  公开（公告）日：2005-12-01

  The invention relates to 3- or 4-monosubstituted phenol and thiophenol derivatives of formula (I) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. Said 3- or 4-monosubstituted phenol and thiophenol derivatives are H 3 ligands and are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic and respiratory diseases, disorders and conditions.

  本发明涉及公式(I)的3-或4-单取代苯酚和硫代苯酚衍生物，以及用于制备这些衍生物的中间体、含有这些衍生物的组合物和这些衍生物的用途的过程。所述的3-或4-单取代苯酚和硫代苯酚衍生物是H3配体，在许多疾病、失调和病况中特别有用，特别是在炎性、过敏和呼吸系统疾病、失调和病况中。
• 2-Imino-benzimidazoles
  申请人：Roth P. Gregory

  公开号：US20070232673A1

  公开（公告）日：2007-10-04

  Novel compounds of Formula (I) or pharmaceutically acceptable salts, prodrugs and biologically active metabolites thereof of Formula (I) wherein the substituents are as defined herein, which are useful as therapeutic agents.

  本发明涉及式（I）的新化合物或其药学上可接受的盐、前药和生物活性代谢物，其中取代基如本文所定义，其作为治疗剂具有用处。